Member Info for Laura2022

Back today

To appear imho judging by the price action and volatility

Real spread 2.5p to 2.68p

Breakout any day after 7 days consecutive above the moving average

Locked and loaded

RCFX only £8mln cap and will be profitable in 12mths

The interview also explored the broader UK defence spending environment and how RC Fornax is positioning itself to benefit from existing Ministry of Defence budgets as well as future investment plans. Shepherd estimated there is a £1 billion to £1.5 billion addressable market opportunity for the company within current defence spending levels

Moving on every buy

Huge £18bln investment coming for UK GOV in defence market

20% up

Cash more than cap and soon to be all debt free

Market cap

Could easily do 500% with right CEO and partnerships with HAYD etc

Blue

Excellent

Holdit

I will be adding ,looks like they're cleaning account before major transaction

Proposed balance sheet strengthening, proposed debt reduction and update on M2G

 

Sabien Technology Group plc (AIM: SNT), the manufacturer and provider of energy reduction technologies, announces a series of actions and proposals designed to strengthen the Group's balance sheet, simplify its corporate structure and enhance its strategic focus on the commercial deployment of its M2G technology platform.

 

Highlights

• £213,708 cash received from b.grn Group Limited ("b.grn") through settlement of management service fees, repayment of an intercompany loan and partial settlement of a fixed profit share entitlement associated with the Company's historical City Oil Field Inc. ("COF") investment.

• Proposal to use a substantial proportion of the proceeds received from b.grn to pay £127,500 to Parris Group Ltd in cash by 30 June 2026 in connection with the related party funding provided to the Company, as announced on 20 August 2024.

• Proposed capitalisation of approximately £179,409 of directors' remuneration accrued in FY2026 through the issue of new ordinary shares of 3 pence each in the share capital of the Company ("Ordinary Shares").

• Settlement of £40,000 of broker fees through the issue of new Ordinary Shares.

• Actions and proposals are expected to materially reduce the Company's liabilities, strengthen the balance sheet and improve the Company's financial flexibility.

• Sabien's direct financial exposure to b.grn will be materially reduced while retaining an equity interest and exposure to potential future value creation. Following these actions, the board of directors of Sabien (the "Board" or the "Directors") believe that the future funding requirements of Sabien and b.grn can be clearly separated and assessed independently.

• Additional funding secured by b.grn to support its ongoing activities and greater financial independence.

• Continued strategic focus on accelerating the commercial deployment of the Group's M2G technology platform and advance the proposals outlined in the Company's announcement on 21 

All the non believers have a chance to vent in person rather than on a Bb :)

ImmuPharma's AGM will be held on Thursday 25th June 2026 @ 11:00am (BST) at the offices of Broadfield Law UK LLP, One Bartholomew Close, London EC1A 7BL.

Ends

Adam

Are the 2 connected ?

Thanks for that information

Full asl buy

At 1.7p and not much left 1.8p

Balance

You've summed up sushi correctly

One of LSEs biggest pests

Thungel

At least 10 people have talked nonsense since the time I started buying here so green boxes are customary:)

P140 partnering discussions

As reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value‑enhancing licensing deal in 2026.